Tong Ren Tang Technologies Announces Board Reshuffle and Proposed Independent Director Appointment

An announcement from Tong Ren Tang Technologies Co ( (HK:1666) ) is now available.

Tong Ren Tang Technologies Co. Ltd. has announced that independent non-executive director Li Siu Bun has tendered his resignation from the board, including his roles as chairman of the audit committee and member of the remuneration and strategy and planning committees, citing work adjustments; his resignation will only take effect once shareholders elect a new independent non-executive director at an upcoming general meeting, and the board has emphasized there is no disagreement or outstanding issue related to his departure. The company’s board has proposed appointing veteran accountant Paul Yu Hay Siu as the new independent non-executive director, subject to shareholder approval, highlighting his extensive leadership experience at Deloitte and current independent directorship in Shanghai, with a proposed annual director’s fee of HKD 288,000 and confirmation of his independence under Hong Kong listing rules, a move that aims to maintain robust corporate governance and continuity in audit oversight for investors and other stakeholders.

The most recent analyst rating on (HK:1666) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Tong Ren Tang Technologies Co stock, see the HK:1666 Stock Forecast page.

More about Tong Ren Tang Technologies Co

Tong Ren Tang Technologies Co. Ltd. is a Hong Kong-listed company (stock code: 1666) associated with the Tong Ren Tang brand, operating in the pharmaceutical and healthcare sector with a focus likely on traditional Chinese medicine products and related health offerings, serving both domestic China and international markets through its listed platform.

Average Trading Volume: 1,217,129

Technical Sentiment Signal: Sell

Current Market Cap: HK$5.75B

See more insights into 1666 stock on TipRanks’ Stock Analysis page.